SG11201912799SA - Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf - Google Patents

Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf

Info

Publication number
SG11201912799SA
SG11201912799SA SG11201912799SA SG11201912799SA SG11201912799SA SG 11201912799S A SG11201912799S A SG 11201912799SA SG 11201912799S A SG11201912799S A SG 11201912799SA SG 11201912799S A SG11201912799S A SG 11201912799SA SG 11201912799S A SG11201912799S A SG 11201912799SA
Authority
SG
Singapore
Prior art keywords
bfgf
pharmaceutical composition
growth factor
recombinant human
fibroblast growth
Prior art date
Application number
SG11201912799SA
Inventor
Haizhou Fang
Peimin Dai
Bo Yang
Xinzhi Wang
Zhenheng Wang
Malcolm Ngiam
Qi Xue
Yingluo Xiong
Original Assignee
Zhuhai Essex Bio Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuhai Essex Bio Pharmaceutical Co Ltd filed Critical Zhuhai Essex Bio Pharmaceutical Co Ltd
Publication of SG11201912799SA publication Critical patent/SG11201912799SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • C07K14/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
SG11201912799SA 2017-06-23 2017-06-23 Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf SG11201912799SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/089823 WO2018232750A1 (en) 2017-06-23 2017-06-23 Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf

Publications (1)

Publication Number Publication Date
SG11201912799SA true SG11201912799SA (en) 2020-01-30

Family

ID=64735425

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912799SA SG11201912799SA (en) 2017-06-23 2017-06-23 Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf

Country Status (8)

Country Link
US (1) US11254723B2 (en)
EP (1) EP3643784A4 (en)
JP (1) JP7044870B2 (en)
KR (1) KR102480402B1 (en)
CN (1) CN111315886A (en)
MY (1) MY194351A (en)
SG (1) SG11201912799SA (en)
WO (1) WO2018232750A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111647089A (en) * 2020-06-30 2020-09-11 安徽九川生物科技有限公司 Recombinant human elastin and composition thereof
TW202233225A (en) * 2020-11-16 2022-09-01 雅祥生技醫藥股份有限公司 Stabilized afgf compositions
CN113274486A (en) * 2021-04-15 2021-08-20 上海腾瑞制药股份有限公司 Stable acidic fibroblast growth factor preparation and preparation method and application thereof
CN116392441B (en) * 2023-04-21 2023-11-28 上海腾瑞制药股份有限公司 Acidic fibroblast growth factor eye drop preparation
CN116889545B (en) * 2023-06-27 2023-12-29 上海腾瑞制药股份有限公司 Recombinant human acidic fibroblast growth factor gel and preparation process thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01291797A (en) * 1987-06-26 1989-11-24 Progen Biotechnik Gmbh Synthetic gene encoding growth factor
CN1448510A (en) 2002-04-04 2003-10-15 北京三元基因工程有限公司 High-efficiency expression of recombination human basic fibroblast growth factor
KR100484653B1 (en) 2004-05-06 2005-04-20 주식회사 대웅 Preparation method for the production of active and soluble proteins in prokaryotes and polycistronic vectors therefor
CN1634567A (en) * 2004-09-28 2005-07-06 广州暨南大学医药生物技术研究开发中心 Process and formula for preparing gelling agent containing alkalic fibroblast growth factor
CN1733294A (en) * 2005-08-10 2006-02-15 南海朗肽制药有限公司 Recombined human alkaline fibroblast growth factor gelling agent and process for preparing the same
US20070185014A1 (en) * 2006-02-09 2007-08-09 The Schepens Eye Research Institute, Inc. Methods and compositions for modulating conjunctival goblet cells
WO2011010399A1 (en) * 2009-07-24 2011-01-27 千寿製薬株式会社 Corneal endothelial cell proliferation promoter
CN101658491B (en) * 2009-09-24 2011-04-13 哈尔滨医科大学 Amnion eye drops for curing cornea alkali burn
CN101947309B (en) * 2010-04-12 2012-09-19 南海朗肽制药有限公司 Human basic fibroblast growth factor eye drops and preparation method thereof
US20110300097A1 (en) * 2010-06-04 2011-12-08 Al-Qahtani Ahmed H Method And Composition For The Treatment Of Moderate To Severe Keratoconjunctivitis Sicca
CN102389392B (en) * 2011-11-02 2012-10-24 珠海亿胜生物制药有限公司 Recombinant bovine basic fibroblast growth factor gel for eye use
CN103667329A (en) * 2012-09-17 2014-03-26 北京双鹭药业股份有限公司 Method of efficiently preparing recombinant human basic fibroblast growth factor
GB2510407A (en) * 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
US20160120693A1 (en) * 2013-05-08 2016-05-05 Optometric Technology Group Eye Care Devices and Methods
CN104606666B (en) * 2015-02-12 2016-03-23 珠海亿胜生物制药有限公司 BFGF bovine basic fibroblast growth factor eye drop
CN104984326A (en) * 2015-07-14 2015-10-21 珠海亿胜生物制药有限公司 Recombinant human basic fibroblast growth factor gel without bacteriostatic agent and preparation method thereof
CN106038350A (en) * 2016-05-31 2016-10-26 南海朗肽制药有限公司 Composite growth factor skincare gel and preparation method thereof
CN107320716B (en) * 2017-06-27 2019-03-05 珠海亿胜生物制药有限公司 Basic fibroblast growth factor vesica and preparation method thereof

Also Published As

Publication number Publication date
JP7044870B2 (en) 2022-03-30
EP3643784A4 (en) 2021-05-05
US11254723B2 (en) 2022-02-22
KR102480402B1 (en) 2022-12-22
EP3643784A1 (en) 2020-04-29
US20200157164A1 (en) 2020-05-21
JP2020533015A (en) 2020-11-19
MY194351A (en) 2022-11-29
CN111315886A (en) 2020-06-19
WO2018232750A1 (en) 2018-12-27
KR20200021521A (en) 2020-02-28

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
SG11201912799SA (en) Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf
ZA201900772B (en) Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
AU2018261021A1 (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
ZA201900507B (en) Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
EP3723771A4 (en) Recombinant adenoviruses and uses thereof
GB2595109B (en) Pharmaceutical delivery compositions and uses thereof
EP3639845C0 (en) Il-15 protein complex pharmaceutical composition and uses thereof
IL287628A (en) Injectable pharmaceutical compositions and uses thereof
EP3711779C0 (en) Application of pharmaceutical composition in regulation of fibroblast growth
EP3362048A4 (en) Composition for intraoral delivery of biologically active peptides and proteins
SG11202006726UA (en) Recombinant vaccinia virus and pharmaceutical composition comprising same
GB2546439B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
IL279877A (en) Ivosidenib forms and pharmaceutical compositions
GB202201001D0 (en) Polypeptide and use thereof
PL3525769T3 (en) Orodispersible tablet comprising burlulipase and its pharmaceutical composition
EP4069233A4 (en) Pharmaceutical combination and use thereof
IL275241A (en) Engineered o-glycosylation in recombinant polypeptides and uses thereof
EP3718543A4 (en) Pharmaceutical composition and use thereof
EP3576767A4 (en) Recombinant proteins and uses thereof
IL279707A (en) Pharmaceutical composition comprising polypeptide
EP3752174A4 (en) Fibroblast growth factor analogs and uses thereof
KR102483495B9 (en) 24- 24-disubstituted pyrimidines and pharmaceutical composition comprising the same
IL272080A (en) Peptide derivative and pharmaceutical composition containing same
EP3980134C0 (en) Bioactive peptides and compositions comprising them